Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

Q: What does this research mean for the field?

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Zi Yun Ng; Laurane Cottin; Marine Demoy; Damien Luque Paz; Corentin Orvain; Wayne‐Corentin Lambert; Jean‐Christophe Ianotto; Éric Lippert; David M. Ross; Diana Iarossi; Alesia Khan; Daniel Lock; Catherine Truong; Kamel Laribi; Yun Fan Yang; Laura Li Gagnon; Valérie Ugo; Claire Harrison; Jennifer O'Sullivan

doi:10.1002/hem3.70460

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Multicenter study reveals allele burden expansion correlates with disease progression and anagrelide therapy in MPN, highlighting tracking utility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ng et al. (2026) studied this question.

synapsesocial.com/papers/6a9934cf636c6408cfa7c9a2 https://doi.org/10.1002/hem3.70460

View Full Paper

Ask AI

Bookmark

Share

Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading